top content border

"Cough It Up, Doc"

If you are a physician or a healthcare professional, we'd love to get your thoughts on the subject of cold or allergy-related cough and its treatment. It's as easy as answering the following questions. Your responses will help us improve the level of information and service that we provide to you and all healthcare professionals. Thank you!

1) Are you a:







2) Do you believe it is important to offer patients a choice of dose form when it is available?




3) If you were prescribed an oral medication, which dose form would you prefer?





4) In your opinion, what are the most important advantages of capsule dosing? (Rank from 1 through 7 with 1 being most important)









5) If you're a prescriber, rate your interest in prescribing TussiCaps® for a patient with a severe cold or allergy-related cough?







6) There are now only 8 hydrocodone-containing cough products on the market. What are your biggest concerns about prescription cough treatments this cough season?







7) Was your prescribing affected by the FDA's 2007 decision to remove nearly 200 prescription cough products from the market?






8) How did you learn about the FDA's decision to remove these products?







  

IMPORTANT RISK INFORMATION
TussiCaps® (hydrocodone polistirex and chlorpheniramine polistirex) extended-release capsules are indicated for relief of cough and upper respiratory symptoms associated with allergy or cold in adults and children 6 years of age and older.

TussiCaps® is contraindicated in the presence of known allergy or sensitivity to hydrocodone or chlorpheniramine. The most common adverse reactions associated with TussiCaps® are sedation, drowsiness, and mental clouding, which may impair the mental and/or physical abilities required for potentially hazardous tasks.

bottom content border
page_bottom border